Mineralys Therapeutics Q2 net loss $43.3M; cash $324.9M; pre-NDA meeting set for Q4 2025

Mineralys Therapeutics, Inc.

2025-Q2 EPS reported -$1.44

Net loss $43.3M vs $41.0M in Q2 2024; R&D expenses $38.3M, G&A $8.5M.
Cash, equivalents and investments $324.9M, sufficient to fund operations into 2027.
Explore-CKD Phase 2 met primary endpoints: 9.25 mmHg systolic BP reduction, 30.51% UACR reduction.
Pre-NDA meeting with FDA scheduled for Q4 2025; Explore-OSA top-line data expected in 1H 2026.
Pivotal Launch-HTN and Advance-HTN results published in JAMA and NEJM.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.